Navigation Links
Spectrum Health to offer implantable neurostimulator for hard-to-treat epilepsy patients
Date:12/11/2013

GRAND RAPIDS, Mich., December 10, 2013 Spectrum Health will be the first health system in West Michigan and among the first in the nation to offer treatment with a newly FDA-approved device that uses electric stimulation of the brain for adult epilepsy patients whose seizures have not responded to medication.

The NeuroPace Responsive Neurostimulation (RNS) System is an implantable therapeutic device designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible electrical stimulation to normalize brain activity before an individual experiences seizures.

"For patients with frequent and disabling partial onset seizures who have proven unresponsive to two or more medications and who are not candidates for actual removal of abnormal tissue, this may prove to be a viable and welcome treatment option," said Kost Elisevich, MD, PhD, neurosurgeon, co-chair department of clinical neurosciences, chief, division of neurosurgery, Spectrum Health Medical Group.

The RNS System is designed for use in combination with other therapies in reducing the frequency of seizures in individuals 18 years of age or older. It is indicated for use in patients with partial onset seizures seizures that originate and remain in a limited area of the brain. To be eligible for the procedure, patients must have frequent and disabling seizures (motor partial seizures, complex partial seizures and/or secondarily generalized seizures), whose origin is limited to two or fewer locations in the brain.

NeuroPace, Inc. estimates that approximately 400,000 people in the U.S. meet these criteria and may benefit from treatment with the RNS System.

"Neurostimulation could provide relief from seizures for many patients who are not good candidates for surgery," said Brien Smith, MD, co-chair, department of clinical neurosciences, chief, division of neurology, Spectrum Health Medical Group, and immediate past chair of the National Epilepsy Foundation. "We plan to offer this treatment to eligible patients as soon as it becomes available."

The U.S. Food and Drug Administration (FDA) granted premarket approval for the RNS System on November 14. While employed at Henry Ford Health System, Drs. Elisevich and Smith were one of the first clinical teams in the nation to participate in clinical trials using the RNS System. The device has been evaluated for more than eight years in three clinical trials at 32 comprehensive epilepsy centers in the U.S., including a prospective, randomized, double-blinded, sham stimulation controlled pivotal study.

The pivotal study demonstrated a nearly 38 percent reduction in seizure frequency in patients treated with responsive stimulation compared to an approximately 17 percent reduction in patients who were implanted with the device but were not receiving responsive stimulation during a three month blinded period. In a two-year follow-up phase, 55 percent of the subjects experienced a 50 percent or greater reduction in seizures.

Treatment with the RNS System will take place in Level 4 epilepsy centers throughout the nation following site qualification and physician training. Spectrum Health is the first epilepsy program in West Michigan to receive a Level 4 designation by the National Association of Epilepsy Centers (NAEC). Level 4 centers have the professional expertise and facilities to provide the highest level of medical and surgical epilepsy evaluation and treatment for patients with epilepsy.


'/>"/>

Contact: Tim Hawkins
timothy.hawkins@spectrumhealth.org
616-486-6091
Spectrum Health
Source:Eurekalert

Related biology news :

1. DNA SPECTRUM LAUNCHES GROUNDBREAKING DNA STORAGE PRODUCT
2. Changes to symptom structure in DSM-5 support diagnosis of toddlers with autism spectrum disorder
3. Toward broad-spectrum antiviral drugs for common cold and other infections
4. Study reveals how common gene mutation affects kids with autism spectrum disorders
5. Can videogaming benefit young people with autism spectrum disorder?
6. Gene mutation identified as contributor to autism spectrum disorders
7. Official opening of wildlife health genetic and forensic laboratory between EcoHealth Alliance and Sabah Wildlife Department
8. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
9. Feeding by tourists compromises health of already-endangered iguanas, study finds
10. UCSB researcher shows microplastic transfers chemicals, impacting health
11. Organovo to Present at the 24th Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology: